Table 1.
Characteristics of the study population n (%)
| Characteristic | Patients |
| (n = 107) | |
| Age, yr (mean ± SD)1 | 47.5 (± 8.8) |
| Gender | |
| Male | 68.2 (73) |
| Female | 31.8 (34) |
| INFL3 polymorphism2 | |
| CT | 56.2 (36) |
| CC | 28.1 (18) |
| TT | 15.7 (10) |
| Pre treatment HCV-RNA3 | |
| < 600000 UI/mL | 44.7 (46) |
| ≥ 6000000 UI/mL | 55.3 (57) |
| Pre treatment elevated ALT4 | 88.5 (92) |
| Fibrosis5 | |
| Mild to moderate6 | 59.8 (61) |
| Advanced7 | 40.2 (41) |
| Steatosis | 47.6 (51) |
| BMI (kg/m2) > 27 | 54.2 (58) |
| Diabetes | 5.6 (6) |
| Type of peginterferon | |
| alfa 2a | 75.7 (81) |
| alfa 2b | 24.3 (26) |
| RBV dose | |
| Fix8 | 63.6 (68) |
| Weight-Based9 | 36.4 (39) |
| 80/80/80 adherence10 | 94.4 (101) |
1
Available for 105 patients;
2
Available for 64 patients;
3
Available for 103 patients;
4
Available for 104 patients;
5
Available for 102 patients;
6
Mild to moderate fibrosis includes patients without fibrosis and patients with up to METAVIR F2 fibrosis;
7
Advanced fibrosis includes patients with METAFIR F3 and cirrhosis;
8
800 mg/d;
9
1000 mg/d in patients ≤ 75 kg weight, 1200 mg/d in patients > 75 kg weight;
10
Patients received at least 80% of the peginterferon and RBV doses, and completed at least 80% of the expected treatment duration. ALT: Alanine aminotransferase; HCV: Hepatitis C virus; RBV: Ribavirin; BMI: Body mass index.